Lijun International Pharmaceutical (Holding) Co., Limited ( simplified Chinese: 利君国际医药(控股)有限公司; traditional Chinese: 利君國際醫藥(控股)有限公司) ( SEHK: 2005) is a Wanchai, Hong Kong-based investment holding company with two pharmaceutical business segments:
Business segments
- manufacturing and selling of intravenous infusion solution
- manufacturing and selling of antibiotics and others
The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005).
The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.
Subsidiaries
The Company’s subsidiaries include:
- New Orient Limited (New Orient) in Hong Kong
- Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province (acquired in June 2007)
- Xi’an Lijun Pharmaceutical Co., Limited (Xi’an Lijun), engaged in manufacturing pharmaceuticals in Shaanxi Province
- Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.
The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.
Facing more merger and acquisition opportunities from medical reform in China, the Group is positioned for continuous mergers and acquisitions to promote its growth.
External links
Lijun International Pharmaceutical (Holding) Co., Limited ( simplified Chinese: 利君国际医药(控股)有限公司; traditional Chinese: 利君國際醫藥(控股)有限公司) ( SEHK: 2005) is a Wanchai, Hong Kong-based investment holding company with two pharmaceutical business segments:
Business segments
- manufacturing and selling of intravenous infusion solution
- manufacturing and selling of antibiotics and others
The Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005).
The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.
Subsidiaries
The Company’s subsidiaries include:
- New Orient Limited (New Orient) in Hong Kong
- Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province (acquired in June 2007)
- Xi’an Lijun Pharmaceutical Co., Limited (Xi’an Lijun), engaged in manufacturing pharmaceuticals in Shaanxi Province
- Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.
The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.
Facing more merger and acquisition opportunities from medical reform in China, the Group is positioned for continuous mergers and acquisitions to promote its growth.